#DelveInsight
T-Cell Malignancies Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
https://www.pressreleasecc.com/2026/11/05/t-cell-malignancies-market-and-pipeline-appear-robust-with-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight
www.pressreleasecc.com
November 18, 2026 at 1:12 PM
Spasticity Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
https://www.pressreleasecc.com/2026/11/05/spasticity-market-and-pipeline-appear-robust-with-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight
www.pressreleasecc.com
November 18, 2026 at 11:12 AM
Cancer Pain Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
https://www.pressreleasecc.com/2026/11/05/cancer-pain-market-and-pipeline-appear-robust-with-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight
www.pressreleasecc.com
November 18, 2026 at 12:12 PM
Antiphospholipid Syndrome (APS) Market is Projected to Grow by 2036 Owing to the Development of Novel Targeted Therapies | DelveInsight
Antiphospholipid Syndrome (APS) Market Is Projected To Grow By 2036 Owing To The Development Of Novel Targeted Therapies | DelveInsight | PressReleaseCC
(Albany, New York) – November 5, 2026 – The market dynamics for Antiphospholipid Syndrome (APS) are expected to witness growth driven by the rising prevalence
www.pressreleasecc.com
November 18, 2026 at 2:12 PM
Pheochromocytoma and Paraganglioma Market Expected to Grow at a CAGR of 7.3% Through 2036, Driven by Targeted Therapies and Emerging Pipeline Developments | DelveInsight
Pheochromocytoma And Paraganglioma Market Expected To Grow At A CAGR Of 7.3% Through 2036, Driven By Targeted Therapies And Emerging Pipeline Developments | DelveInsight | PressReleaseCC
(Albany, US) On November 05, 2026, DelveInsight’s “Pheochromocytoma and Paraganglioma (PCPG) Market Insights, Epidemiology and Market Forecast – 2036” report
www.pressreleasecc.com
November 18, 2026 at 1:45 PM
Buerger’s Disease Market is Projected to Evolve by 2036 Owing to the Growing Focus on Vascular Regeneration and Emerging Therapeutic Approaches | DelveInsight
Buerger’s Disease Market Is Projected To Evolve By 2036 Owing To The Growing Focus On Vascular Regeneration And Emerging Therapeutic Approaches | DelveInsight | PressReleaseCC
(Albany, New York) – November 5, 2026 – The market dynamics for Buerger’s disease are expected to evolve through 2036, driven by the high unmet medical need
www.pressreleasecc.com
November 18, 2026 at 3:12 PM
Dry Eye Disease Pipeline Report 2026: Discover Novel Drug Candidates, Ongoing Trials, and Major Players Shaping Future Care | Laboratorios Sophia, Iolyx Therapeutics, Oculis Pharma, HanAll BioPharma
Dry Eye Disease Pipeline Report 2026: Discover Novel Drug Candidates, Ongoing Trials, And Major Players Shaping Future Care | Laboratorios Sophia, Iolyx Therapeutics, Oculis Pharma, HanAll BioPharma | PressReleaseCC
“Dry Eye Disease Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth
www.pressreleasecc.com
November 17, 2026 at 8:45 AM
Postpartum Depression Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
https://www.pressreleasecc.com/2026/11/04/postpartum-depression-market-and-pipeline-appear-robust-with-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight
www.pressreleasecc.com
November 10, 2026 at 5:12 PM
Rare NRG1 Fusion Market Size in the 7MM is projected to increase over the forecast period of 2024-2034 | DelveInsight
https://www.pressreleasecc.com/2026/11/04/rare-nrg1-fusion-market-size-in-the-7mm-is-projected-to-increase-over-the-forecast-period-of-2024-2034-delveinsight
www.pressreleasecc.com
November 10, 2026 at 7:12 PM
Gastroesophageal Reflux Disease Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
https://www.pressreleasecc.com/2026/11/04/gastroesophageal-reflux-disease-market-and-pipeline-appear-robust-with-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight
www.pressreleasecc.com
November 10, 2026 at 1:45 PM
Brain Cancer Market Size in the 7MM is projected to grow at a CAGR of 2.5% over the forecast period of 2026-2036 | DelveInsight
https://www.pressreleasecc.com/2026/11/04/brain-cancer-market-size-in-the-7mm-is-projected-to-grow-at-a-cagr-of-2-5-over-the-forecast-period-of-2026-2036-delveinsight
www.pressreleasecc.com
November 10, 2026 at 6:13 PM
Immune Complex Membranoproliferative Glomerulonephritis Market Size in the 7MM is projected to grow at a 26% CAGR over the forecast period of 2026-2036 | DelveInsight
https://www.pressreleasecc.com/2026/11/04/immune-complex-membranoproliferative-glomerulonephritis-market-size-in-the-7mm-is-projected-to-grow-at-a-26-cagr-over-the-forecast-period-of-2026-2036-delveinsight
www.pressreleasecc.com
November 10, 2026 at 12:12 PM
Parkinson’s Disease Market: Accelerating Growth and Pipeline Impact by 2036 – DelveInsight | Roche, Amneal Pharma, AbbVie, Supernus Pharma, Britannia Pharma, AbbVie, Cerevel Therapeutics, Pharma Two
https://www.pressreleasecc.com/2026/11/04/parkinsons-disease-market-accelerating-growth-and-pipeline-impact-by-2036-delveinsight-roche-amneal-pharma-abbvie-supernus-pharma-britannia-pharma-abbvie-cerevel-therapeuti
www.pressreleasecc.com
November 10, 2026 at 7:45 AM
Asthma Market Set for Robust Growth Driven by Innovation and Pipeline Advances by 2036 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Phrma, Sanofi
https://www.pressreleasecc.com/2026/11/04/asthma-market-set-for-robust-growth-driven-by-innovation-and-pipeline-advances-by-2036-delveinsight-glaxosmithkline-ab-science-areteia-therapeutics-ars-pharma-astrazeneca-pieris-phrma
www.pressreleasecc.com
November 10, 2026 at 10:12 AM
Gastroenteropancreatic Neuroendocrine Tumors Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight
Gastroenteropancreatic Neuroendocrine Tumors Market Size In The 7MM Is Projected To Grow At A Significant CAGR Over The Forecast Period Of 2026-2036 | DelveInsight | PressReleaseCC
(Albany, US), November 04, 2026 – DelveInsight’s ‘Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Market Insights, Epidemiology and Market Forecast –
www.pressreleasecc.com
November 10, 2026 at 1:12 PM
Frontotemporal Dementia Market Size in the 7MM is projected to grow at a ~15% CAGR over the forecast period of 2026-2036 | DelveInsight
https://www.pressreleasecc.com/2026/11/03/frontotemporal-dementia-market-size-in-the-7mm-is-projected-to-grow-at-a-15-cagr-over-the-forecast-period-of-2026-2036-delveinsight-2
www.pressreleasecc.com
November 5, 2026 at 3:35 AM
Synovial Sarcoma Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
https://www.pressreleasecc.com/2026/11/03/synovial-sarcoma-market-and-pipeline-appear-robust-with-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight
www.pressreleasecc.com
November 4, 2026 at 9:12 PM
Amyloidosis Market is Projected to Boom by 2036 Owing to the Advancement of Novel Therapies and Increasing Disease Awareness | DelveInsight
https://www.pressreleasecc.com/2026/11/03/amyloidosis-market-is-projected-to-boom-by-2036-owing-to-the-advancement-of-novel-therapies-and-increasing-disease-awareness-delveinsight-2
www.pressreleasecc.com
November 4, 2026 at 8:12 PM
Checkpoint Inhibitor Refractory Cancer Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
https://www.pressreleasecc.com/2026/11/03/checkpoint-inhibitor-refractory-cancer-market-and-pipeline-appear-robust-with-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight
www.pressreleasecc.com
November 4, 2026 at 7:12 PM
Heart Failure Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Abbott, Berlin Heart GmbH, Biotronik, Boston Scientific Corp, Jarvik Heart Inc
https://www.pressreleasecc.com/2026/11/03/heart-failure-pipeline-2026-moa-roa-fda-approved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-abbott-berlin-heart-gmbh-biotronik-boston-scientific-corp-jarvik-heart-inc
www.pressreleasecc.com
November 5, 2026 at 1:12 AM
Chronic Pain Associated With Painful Diabetic Neuropathy Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
https://www.pressreleasecc.com/2026/11/03/chronic-pain-associated-with-painful-diabetic-neuropathy-market-and-pipeline-appear-robust-with-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight
www.pressreleasecc.com
November 4, 2026 at 8:52 PM
Hashimoto’s Thyroiditis Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight
https://www.pressreleasecc.com/2026/11/03/hashimotos-thyroiditis-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-2026-2036-delveinsight-2
www.pressreleasecc.com
November 4, 2026 at 6:13 PM
Hashimoto’s Thyroiditis Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight
https://www.pressreleasecc.com/2026/11/03/hashimotos-thyroiditis-market-size-in-the-7mm-is-projected-to-grow-at-a-significant-cagr-over-the-forecast-period-of-2026-2036-delveinsight-2
www.pressreleasecc.com
November 4, 2026 at 5:12 PM
Mucopolysaccharidosis I Market Size in the 7MM is projected to grow at a CAGR of 8.6% over the forecast period of 2026-2036 | DelveInsight
https://www.pressreleasecc.com/2026/11/03/mucopolysaccharidosis-i-market-size-in-the-7mm-is-projected-to-grow-at-a-cagr-of-8-6-over-the-forecast-period-of-2026-2036-delveinsight
www.pressreleasecc.com
November 4, 2026 at 3:12 PM